New eye drug trial aims for safer wet AMD treatment
NCT ID NCT05904691
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental drug called OCU-10-C-110, given as an eye injection, in 24 people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability at different doses. Researchers will monitor for side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OCU-10-C-110 (an experimental drug injection)
What this could lead to
If successful, this could lead to a new treatment option for wet age-related macular degeneration, potentially reducing the need for frequent eye injections.
What could go wrong
This is a very early Phase 1 trial with only 24 people, focused on safety. It is too soon to know if the drug works, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Raj K. Maturi, M.D., P.C.
Carmel, Indiana, 46290, United States
-
Retina Research Institute of Texas
Abilene, Texas, 79606, United States
-
Strategic Clinical Research Group LLC
Willow Park, Texas, 76087, United States